Polygala extract for the treatment of major depressive disorder
US11554154B2 · kind B2 · utility
0Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 22, 2020 |
| Grant date | Jan 17, 2023 |
| Priority date | — |
| Expiry date | Jul 22, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2236/333
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to a method of treating Major depressive disorder by orally administering to a subject a composition containing a Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). A solid dosage form of PDC-1421 can be prepared into the gelatin capsule. The oral administration of PDC-1421 in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extraction.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.